Chelsea Mayoh

Nov 5, 2024 | nature.com | Hansen Kosasih |Chelsea Mayoh |Michelle Henderson |Toby Trahair |Adam Patterson

AbstractT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed a novel prodrug, ACHM-025, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent.

Oct 13, 2024 | nature.com | Belamy B. Cheung |Qian Wang |Janith A. Seneviratne |Andrew Gifford |Chelsea Mayoh |Lin Luo | +8 more

AbstractMYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders which had lost tumorigenesis. Sequencing of the mutant mouse genomes identified the Ring Finger Protein 121 (RNF121WT) gene mutated to RNFM158R associated with heritable loss of tumorigenicity.

Jun 6, 2024 | nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more

AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).

Jun 6, 2024 | nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more

AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).